Erschienen in:
01.10.2013 | News item
Antimalarial's label updated to warn of visual impairment, sometimes permanent
Erschienen in:
Reactions Weekly
|
Ausgabe 1/2013
Einloggen, um Zugang zu erhalten
Excerpt
■
The Australian TGA is alerting healthcare professionals to new information added to the label of Lariam [mefloquine] regarding the potentially associated risk of eye disorders, including cataract, retinal disorders and damage to the optic nerve, occurring during treatment or up to several weeks after treatment. Symptoms of these eye disorders include visual impairment and blurred vision. In some cases patients have slowly recovered; however, there have also been reports of permanent damage.
1 …